Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma

被引:0
作者
Visca, P
Sebastiani, V
Pizer, ES
Botti, C
De Carli, P
Filippi, S
Monaco, S
Alo, PL
机构
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy
[2] Regina Elena Inst Canc Res, IFO, Dept Pathol, Rome, Italy
[3] Regina Elena Inst Canc Res, IFO, Dept Surg, Rome, Italy
[4] Regina Elena Inst Canc Res, IFO, Dept Urol, Rome, Italy
[5] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
关键词
FAS; GLUT1; bladder; carcinoma; prognosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fatty Acid Synthase (FAS) and Human Erythrocyte Glucose Transporter 1 (GLUT1) are new markers involved in the biological activities of cancer cells. FAS is a multifunctional enzyme that synthesizes palmitate from acetylCoA and malonyl-CoA. GLUT1 is a transmembrane protein normally expressed in perineurium and erythrocytes. FAS and GLUT1 expression have been recently described in many aggressive tumors. We explored the immunohistochemical expression of FAS and GLUT1 in bladder carcinomas to reveal statistical associations with clinico-pathological features and recurrence. Materials and Methods: Thirty-one node-and distant metastasis-negative transitional cell carcinomas from patients with a five-year follow-up, were evaluated for FAS and GLUT1 expression. Results: Univariate analysis showed that low-grade, pTa stage and FAS-negative expression were associated with indolent tumors. Multivariate analysis showed that FAS expression (p=0.006) and pT1-2 stage tumors (p=0.001) were independent predictors of recurrence. Conclusion: Endogenous fatty acids are an exploitable storage of energy for aggressive human bladder carcinomas. Glucose uptake is not required by bladder tumors.
引用
收藏
页码:335 / 339
页数:5
相关论文
共 38 条
[1]  
*ACS, 1998, AJCC CANC STAG MAN
[2]  
Alo P L, 1999, Ann Diagn Pathol, V3, P287, DOI 10.1016/S1092-9134(99)80024-0
[3]  
Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO
[4]  
2-K
[5]  
Alò PL, 2000, ONCOL REP, V7, P1383
[6]  
BADALAMENT RA, 1992, UROL CLIN N AM, V19, P485
[7]   Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia [J].
Baer, SC ;
Casaubon, L ;
Younes, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (04) :575-577
[8]   THE HUMAN BRAIN GLUT1 GLUCOSE-TRANSPORTER - ULTRASTRUCTURAL-LOCALIZATION TO THE BLOOD-BRAIN-BARRIER ENDOTHELIA [J].
CORNFORD, EM ;
HYMAN, S ;
SWARTZ, BE .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1994, 14 (01) :106-112
[9]  
Gabrielson EW, 2001, CLIN CANCER RES, V7, P153
[10]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33